OCRF Research Finds New “Chemoimmunotherapy” Ma...
OCRF Research Finds New “Chemoimmunotherapy” May Be New Treatment Option
New research funded by OCRF shows that treatment with the drug decitabine, prior to administration of chemotherapy and a cancer vaccine, yielded clinical benefit for women with recurrent ovarian cancer. This suggests that this combinatorial “chemoimmunotherapy” may provide a new treatment option for patients with this disease. Results of this phase I clinical trial, which … Continued